A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Inclusion Criteria: 1. Ability to understand and the willingness to sign a written informed consent document； 2. Aged ≥18 years old; 3. Histologically or cytologically confirmed advanced or metastatic malignant tumor; 4. Presence of at least one measurable lesion in agreement to RECIST criteria; 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1; 6. Life expectancy ≥3 months; 7. Adequate organ performance based on laboratory blood tests; 8. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Exclusion Criteria: 1. Previous received anti-cancer systemic therapy including chemo-therapy, radiation therapy, target therapy or immuno-therapy within 4 weeks before the first dose; 2. Previous received experimental medication or therapy within 4 weeks before the first dose; 3. Previous therapeutic surgery within 4 weeks; 4. Has unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to NCI-CTCAE version 5.0 grade ≤ 1. 5. Known allergic to any compound of SHR-A2102; 6. Patients with uncontrolled or active brain metastasis； 7. Patients with clinical significant lung disease; 8. Patients with history of autoimmune diseases; 9. Known active hepatitis B or C infection; 10. Other serious accompanying illnesses, which, in the investigator's assessment, could seriously adversely affect the safety of the treatment.